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Abstract: Diabetic foot ulcers (DFUs) are one the common complications of diabetes mellitus. Many
trials were performed to evaluate the effect of recombinant human epidermal growth factor (rhEGF)
in healing DFUs. This meta-analysis was performed to synthesize the evidence of rhEGF treatment
in DFUs in comparison to placebo. Databases included for the search were PubMed, EMBASE,
the Cochrane Library, Web of Science, EBSCOhost, ScienceDirect, and Scopus (up to January 2019).
The outcome of interest was the complete healing rate of DFUs. We performed random effects
meta-analysis stratified by the types of administration route (intralesional injection and topical apply)
by calculating the odds ratios (OR) and 95% confidence interval (95% CI). A total of six studies
involving 530 patients were eligible for analysis. The combined OR (intralesional injection and topical
apply) was 4.005 (95% CI: (2.248; 7.135), p < 0.001). The ORs for intralesional injection and topical
application were 3.599 (95% CI: (1.213; 10.677), p = 0.021) and 4.176 (95% CI: (2.112; 8.256), p < 0.001),
respectively. Statistical heterogeneity might not be important in overall treatment (I2 = 15.17, p = 0.317)
and both of the subgroups (I2: 24.56, p = 0.25 and I2: 33.26, p = 0.213, respectively). Our results
support the use of rhEGF in the treatment of DFUs.
Keywords: recombinant human epidermal growth factor; placebo; diabetic mellitus; diabetic foot
ulcer; meta-analysis
1. Introduction
Diabetes mellitus (DM) is caused by a deficiency of either insulin production or insulin
function. Untreated or inadequately treated DM results in many complications, such as
micro-vasculopathy (including retinopathy, nephropathy, and neuropathy) and macro-vasculopathy
(including cardiovascular disease and insufficient blood flow to lower limbs) [1]. Neuropathy is the
main etiology of diabetic foot ulcers (DFUs). The mechanism of this includes direct damage to the nerve
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by hyperglycemia and a decrease in blood flow to the nerves by damaging small blood vessels. This
nerve damage often results in sensory loss and damage to lower limbs which the patient is unaware
of [2]. Based on some estimations made in 2017, DM affects 451 million people aged between 18 and 82
worldwide, with a global expenditure on DM of 850 billion USD [3,4]. The global prevalence of diabetic
foot ulcers was 6.3%, with North America having the highest (13%) and Oceania having the lowest
values (3%). The prevalence was 5.5%, 5.1%, and 7.2% in Asia, Europe, and Africa, respectively [3].
Indeed, DM is one of the leading causes of non-traumatic lower extremity amputation.
According to the National Institute for Health Care Excellence guidelines (NICE guidelines
(NG19) 2016) and Wound Healing Society (WHS) guidelines, the treatment for DFUs remains to be the
standard of care, which includes offloading, infection control, ischemia control, wound debridement,
and wound dressing [5,6]. However, in the NICE guidelines, it is emphasized that electrical stimulation
therapy, autologous platelet-rich plasma, regenerative wound matrices, dalteparin, and growth factors
(including granulocyte colony-stimulating factor (G-CSF), platelet-derived growth factor (PDGF),
epidermal growth factor (EGF), and transforming growth factor beta (TGF-β)) are not recommended,
unless as part of a clinical trial.
Based on the results of a systematic review assessing a variety of growth factor functions, growth
factors may contribute to achieving the complete healing of foot ulcers in patients with DM [7]. EGF,
previously known as urogastrone, stimulates cell proliferation, differentiation, and survival by binding
to the EGF receptor [8,9]. By exploiting this function, recombinant EGF is manufactured and marketed
under the brand name Heberprot-P®25/75 (Heber Biotec, S.A. La Habana, Cuba) -intralesional injection
form, Regen-D™ 150 (Bharat Biotech, Hyderabad, India) -ointment form and Easyef 0.005% (Daewoong
Pharmaceutical Co., Seoul, South Korea) -spray form. Our hypothesis is that the application of rhEGF
will facilitate the healing process of DFUs.
2. Methodology
The meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement, and was registered in the international prospective register of
systematic reviews (PROSPERO) with registration number CRD42019126404.
2.1. Information Source and Search Strategy
The literature search was performed in PubMed, EMBASE, the Cochrane Central Register of
Controlled Trials (CENTRAL), Web of Science, EBSCOhost, ScienceDirect, and Scopus databases until
10 January 2019. The key terms were diabetic foot, diabetic foot ulcer, diabetic ulcer, diabetes and
recombinant human epidermal growth factor, rhEGF, epidermal growth factor, EGF, urogastron*. Only
an English language filter was applied. All the relevant articles included for the analysis were imported
and selected manually on Endnote x9 software.
2.2. Eligibility, Study Selection, and Data Extraction
Randomized, placebo-controlled trials evaluating the effects of rhEGF administration (intralesional
injection, topical-gel, cream) in patients with DFUs were included.
Title, abstract, and full text base screening were performed by three independent investigators
(T.Q.B, Q.V.P.B, and O.V). One investigator (T.Q.B) extracted the data from eligible studies and two
investigators (Q.V.P.B, O.V) checked for data accuracy.
The following data were extracted from the eligible studies: name of the first author, year of
publication, study design, demographic information, patient data, ulcer baseline data, interventional
data, and outcome data, including primary outcomes—such as complete healing rate, ulcer size change,
granulation response, and days to complete healing—and secondary outcomes—healing velocity,
hospital stay, days to 50% wound size reduction, and percentage of patients with adverse events.
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2.3. Data Synthesis and Analysis
Statistical analysis was performed using Comprehensive Meta-Analysis (version 3.3, Biostat,
INC., Engelwood, MJ, USA). The primary outcome included in the analysis was the complete healing
rate of DFUs. A subgroup analysis was performed, in which we divided the studies based on the
administration route (intralesional injection versus topical). In addition, correlations between the
complete healing rate and mode of drug administration were analyzed using logit regression, to decide
the optimal route for applying rhEGF. The odds ratio (OR) and 95% confidence interval (95% CI) were
calculated. When an OR was more than 1, it indicated that rhEGF treatment was favored over placebo.
Heterogeneity between the studies in effect measures was assessed using both Q and I2 tests. Bases
on Cochrane’s Handbook, a rough classification of the I2 index value is the following: low (0–40%),
moderate (30–60%), substantial (50–90%), and considerable heterogeneity (75–100%) [10]. Depending
on the similarity of the studies, a fixed or random effect model was used to handle heterogeneity.
The effect sizes of the studies were visualized by a forest plot.
2.4. Risk of Bias
Quality assessment was performed using the Cochrane Risk-of-Bias Assessment Tool for
Randomized Control Trials. We assessed the random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and personnel (performance bias), blinding of
outcome assessment (detection bias), incomplete outcome data (attrition bias), and other bias. For each
domain, studies were judged to have either a high (red), unclear (yellow), or low (green) risk of bias.
The risk of bias summary table and graph were regenerated by the RevMan software (version 5.3.
Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Denmark).
2.5. Publication Bias
Publication bias was assessed using funnel plot techniques. If asymmetry was found in a funnel
plot, Begg’s rank test and Egger’s regression test would be used in advance.
2.6. Quality of Evidence
Quality of evidence on the complete healing rate was estimated using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) approach.
2.7. Sensitivity Analysis
Sensitivity analysis was performed by omitting any study (one by one) from the pooled analysis,
then ORs on the complete healing rate were recalculated to study the impact of each individual study
on the summary estimate.
3. Results
3.1. Study Selection
Eligible randomized controlled trials (RCTs) were selected according to the PRISMA flowchart
presented in Figure 1. Seven studies were found to be eligible for qualitative analysis [11–17] and six
of those were included in the quantitative synthesis (meta-analysis). The study of Xu et al. published
in 2018 was excluded from our meta-analysis due to unavailable data on the complete healing rate;
instead, the study mainly focused on healing time (wound healing initiation time, 50% wound surface
healing time, and complete wound healing time) [17].
Int. J. Environ. Res. Public Health 2019, 16, 2584 4 of 13
Int. J. Environ. Res. Public Health 2018, 15, x FOR PEER REVIEW  4 of 13 
 
Figure 1. Flowchart illustrate the screening process for the inclusion of eligible studies for meta-
analysis. 
3.2. Study Characteristic 
The basic characteristics of six studies, which included RCTs, for meta-analysis are shown in 
Tables 1 and 2. The included studies were performed in five countries, Iran, India, China, Korea, 
Cuba, and Mexico, and were published between 2008 and 2018. In these studies, patients received 
either rhEGF or placebo intervention, in addition to standard diabetic foot management. The rhEGF 
and placebo treatments were administrated by intralesional injection or topical application. A total 
of 610 patients were recruited in all the studies and 540 patients completed the study periods, 307 of 
whom received rhEGF treatment and 233 of whom received placebo treatment. All patients were 
diagnosed with either type 1 or 2 DM and developed DFUs. Patients’ ages ranged from 18 to 82 years. 
The mean duration of DM ranged from 9.05 to 17.3 years and mean ulcer duration ranged from 4.3 
to 59.7 weeks. Complete healing rate was studied throughout all the included studies. In addition, 
healing velocity, time to archive 50% reduction, time to complete ulcer healing, and granulation 
response were also studied in the study, as performed by Park et al. [16] and Xu et al. [17]. 
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3.2. Study Characteristic
The basic characteristics of six studies, which included RCTs, for meta-analysis are shown in
Tables 1 and 2. The included studies were performed in five countries, Iran, India, China, Korea, Cuba,
and Mexico, and were published between 2008 and 2018. In these studies, patients received either
rhEGF or placebo intervention, in addition to standard diabetic foot management. The rhEGF and
placebo treatments were administrated by intralesional injection or topical application. A total of 610
patients were recruited in all the studies and 540 patients completed the study periods, 307 of whom
received rhEGF treatment and 233 of whom received placebo treatment. All patients were diagnosed
with either type 1 or 2 DM and developed DFUs. Patients’ ages ranged from 18 to 82 years. The mean
duration of DM ranged from 9.05 to 17.3 years and mean ulcer duration ranged from 4.3 to 59.7 weeks.
Complete healing rate was studied throughout all the included studies. In addition, healing velocity,
time to archive 50% reduction, time to complete ulcer healing, and granulation response were also
studied in the study, as performed by Park et al. [16] and Xu et al. [17].
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Table 1. Study and patient characteristics with the corresponding type of intervention, from studies included for meta-analysis (NA: not available).
Author Year of
Publication
Study
Design
Demography
Intervention Type Route Apply Frequency
Treatment
Duration
(weeks)
Patient Data
Country Number ofCenters
Number of
Patients
Age ± SD
(Years)
Type of
DM
Duration of
Diabetes ± SD
(Years)
Tsang 2003 RCT China 1
Actovecgin %
Topical Once a day 12
19 64.37 ± 11.67
1 or 2
10.11 ± 8.29
0.02 wt% rhEGF 21 68.76 ± 10.34 9.85 ± 7.79
0.04 wt% rhEGF 21 62.24 ± 13.68 9.005 ± 6.19
Afshari 2005 RCT Iran 1
1000 mg 1%
sulfadiazine Topical Once a day 8
20 55.84
1 or 2
NA
1 mg rhEGF in 1000
mg 1% sulfadiazine 30 58.8 NA
Fernández-
Montequín 2009 RCT
Cuba 20
Placebo
Intralesional
injection
Three times a week
on alternate days 8
32 NA
1 or 2
15
25 µ/g 33 NA 15
75 µ/g 44 NA 19.5
Gomez-Villa 2014 RCT Mexico 2
Placebo Intralesional
injection
Three times a week
on alternate days 8
16 55.1 ± 10.6
1 or 2
15.3 ± 8.4
75 µ/g 15 62.1 ± 12.8 17.3 ± 10
Singla 2014 RCT India 1
Betadine
Topical Once every two
weeks
8
25 55.84
1 or 2
NA
Urogastrone
(rhEGF) gel 15 g 24 58.8 NA
Park 2018 RCT Korean 6
Saline
Topical Twice a day 12
72 59.31 ± 12.64
1 or 2
NA
0.005% rhEGF
spray 69 56.52 ± 12.71 NA
Xu 2018 RCT China 1
Saline
Topical Once a day 8
49 63 ± 4.56
1 or 2
NA
40 IU/cm2 50 65 ± 3.65 NA
Abbreviations: rhEGF (recombinant human epidermal growth factor); SD (standard deviation); DM (diabetes mellitus); NA (not available).
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Table 2. Patient ulcer data with the corresponding intervention type (NA: not available).
Author Intervention Type Route Apply Frequency
Treatment
Duration
(weeks)
Ulcer Data
Location Severity Ischemia Level Infection Ulcer Area ±SD (cm2)
Ulcer
Duration ±
SD (Weeks)
Complete
Healing
Rate (%)
Tsang 2003
Actovecgin %
Topical Once a day 12
Foot
Wagner 1 or 2 ABI ≥ 0.7 NA
3.48 ± 0.82 12 ± 15.47 42.1
0.02 wt% rhEGF Foot 3.4 ± 1.1 11.48 ± 14.68 57.14
0.04 wt% rhEGF Foot 2.78 ± 0.82 8.24 ± 5.55 95.3
Afshari
2005
1000 mg
1%sulfadiazine
Topical Once a day 8
Foot
Wagner 1 or 2
ABI < 1: 49% participants
NA
103.4 ± 147.8 59.7 ± 55.5 10
1 mg rhEGF in
1000 mg 1%
sulfadiazine
Foot ABI < 1: 50% participants 87.5 ± 103.2 42.9 ± 38.4 23.3
Fernández-
Montequín
2009
placebo
Intralesional
injection
Three times a week
on alternate days 8
Foot
Wagner 3 or 4 Hemoglobin ≥100 g/L NA
21.8 4.9 52.1
25 µ/g Foot 4.3 20.1 52.1
75 µ/g Foot 4.3 28.5 75.5
Gomez-Villa
2014
Placebo Intralesional
injection
Three times a week
on alternate days 8
Foot Texas 1, 2, and
3
ABI > 0.6 NA
11.9 ± 11.8 15.3 ± 8.4 0
75 µ/g Foot 19.2 ± 15.7 25.8 ± 44 23.5
Singla 2014
Betadine
Topical Once every
two weeks
8
Foot
Wagner 1 or 2 ABI ≥ 0.75 NA
NA NA 12
Urogastrone
(rhEGF) gel 15 g Foot NA NA 48
Park 2018
Saline
Topical Twice a day 12
Foot
Wagner 1 or 2
TcPO2 ≥ 30 mmHg or
palpable dorsalis pedis artery
or posterior tibial artery
NA
2.35 ± 2.69 29.6 ± 60.2 50.6
0.005% rhEGF
spray Foot 2.8 ± 3.72 38.48 ± 70.24 73.2
Xu 2018
Saline
Topical Once a day 8
Foot
Wagner 1 or 2 NA NA
2.35 ± 2.69 29.6 ± 60.2 NA
40 IU/cm2 Foot 2.8 ± 3.72 70.24 ± 38.48 NA
Abbreviations: rhEGF (recombinant human epidermal growth factor); ABI (ankle-brachial index); TcPO2 (transcutaneous oxygen pressure); SD (standard deviation); NA (not available).
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3.3. Odds Ratio of Complete Healing Rate with rhEGF Versus Placebo
Statistical analysis results are shown in Figure 2. The overall OR was 4.005 (95% CI: (+2.248;
+7.135), p < 0.001) and the subgroup ORs of intralesional injection and topical application were 3.599
(95% CI: (+1.213; +10.677), p = 0.021) and 4.176 (95% CI: (+2.112; +8.256), p < 0.001), respectively.
Heterogeneity was found to exist overall (I2 = 15.17, p = 0.317) and in both the intralesional injection
and topical application subgroups (I2 = 24.56, p = 0.25 and I2 = 33.26, p = 0.213, respectively). Meta
regression analysis on the correlation between the rhEGF application frequency and complete healing
rate resulted in a linear correlation, although it was insignificant (Figure 3).
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3.4. Quality of Evidence
In our meta-analysis, only randomized control trials were included. The overall quality of evidence
on rhEGF treatment was moderate. Extra assessment was performed in correlation with different
administration routes. The results of our GRADE analysis reported low evidence on using rhEGF via
these routes. Downgrading factors commonly seen in our GRADE approach were publication bias and
risk of bias. Details are shown in Appendix A, Figure A1.
3.5. Risk of Bias Assessment
Details on the risk of bias assessment are illustrated in Figures 4 and 5. The quality assessment
was performed on a total of six studies, included in qualitative analysis, with the results showing
mostly a low and unclear risk of bias. By converting the Cochrane Risk of Bias Tool to Agency for
Healthcare Research and Quality (AHQR) standard, our risk of bias assessment reported a fair quality.
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3.7. Sensitivity Analysis
Detail on sensitivity analysis are shown in Figure 7. The direction and magnitude of combined
ORs with the respective omitted studies did not change significantly.
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4. Discussion
This meta-analysis was designed to synthesize the currently available evidence on the usage of
rhEGF in treating diabetic foot ulcers. According to the most recent guidelines of the Wound Healing
Society (WHS), discussing the use of adjuvant on diabetic wounds, epidermal growth factor has not
been proven to increase the proportion of wounds that heal or the healing rate of DFUs [6]. Seven
studies were found to study the healing process of DFUs under rhEGF treatment in comparison to
placebo. However, only six studies had data on the complete healing rate as their primary outcome,
and these studies were pooled into our meta-analysis. Our results indicate that the use rhEGF together
with standard wound care facilitates significantly improves healing rate compared to the placebo
control in DFU treatments. This result is consistent with the findings of the previous meta-analysis [19].
However, in addition to the questions of the previous meta-analysis, a question with practical relevance
has addressed the efficacy of rhEGF applied by different methods—intralesional injection or topical
application. A subgroup analysis, categorized by the route of administration, was carried out to ensure
the efficacy of rhEGF, which was maintained regardless of the administration route. Furthermore, we
managed to determine the optimal way (intralesional injection or topical application) of delivering
rhEGF in patients with DFUs. According to Berlanga-Acosta et al, parenteral administration of EGF on
epithelial tissue provides the most effective healing for diabetic foot ulcers [20]. Our work could not
confirm the aforementioned experiment result, however, this contradiction might be partly explained
by the low number of eligible studies in each subgroup. Low heterogeneity (0–40%) was found in the
overall and subgroup analyses.
Although rhEGF was reported to significantly facilitate the healing process in DFUs, based on our
meta-analysis result, the therapeutic management of DFUs is a multidisciplinary approach. Proper
wound care is a key component during the treatment, but it is not sufficient. Many other factors,
like offloading, infection control, ischemia control, and glycemic control, must also be taken into
consideration, along with local wound care. Such complexity may limit the reproducibility of our
results in every day clinical care.
An important strength of our meta-analysis is that with six clinical trials, we confirmed the
efficacy of rhEGF in DFU treatment. Compared to the previous meta-analysis, our meta-analysis
included two recent clinical trials, providing greater evidence. This is important, since the number of
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studies related to rhEGF and DFU treatment is still limited. The efficacy of rhEGF has been proven
in both the intralesional injection and topical application routes. An insignificant linear correlation
between application frequency and complete healing rate has been found, suggesting that increasing
the frequency of applying rhEGF may result in a faster DFU healing rate.
A possible limitation of our meta-analysis is that even though publication bias analysis was
performed, with results indicating it unlikely to occur, the tests were underpowered by the low number
of studies. The risk of bias assessment resulted in a fair quality, which may raise questions about the
validity of the findings, as well as the design and execution of each individual study concerning rhEGF
treatment. As a consequence, our work may either over- or underestimate the true effect of rhEGF
in the treatment of DFUs during daily clinical practice. The GRADE approach on rhEGF treatment
found low evidence. Thus, the effect estimate of rhEGF may be limited, and the true effect may be
substantially different from the estimate effect. In our meta-analysis, important clinical aspects on
medication, like optimal administration route, dose, and treatment duration, could not be covered,
and thus they remain unclear. The amount of data on adverse effects was also limited, and hence
we could not elicit the most common side effect experienced as a result of rhEGF treatment. In the
recent advances in genetics, genes were also identified to play an essential role in DFU initiation and
progression [21]. Therefore, there could be new genetic drug targets identified and new medicine
developed for the novel treatment of DFUs.
5. Conclusions
Our meta-analysis supports the use of rhEGF in facilitating the healing process of DFUs. However,
this conclusion should be considered with caution. The number of studies was limited, as well as
numerous factors which were not taken into consideration when studying the efficacy of rhEGF.
This reflects the need for more well-designed RCTs concerning rhEGF and DFU treatment. It is
recommended that future designs include relevant data such as the patient glycemic profile. This
is to ensure adequate glycemic control during rhEGF therapy. The patients’ general condition and
co-morbidity are important clinical aspects. These are also recommended to be studied alongside
rhEGF treatment, as they may interfere with the healing process of DFUs.
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